Risk of musculoskeletal disorders associated with Bruton’s tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysis
Findings from FAERS and meta-analysis suggest a stronger association between BTKis, particularly ibrutinib, and musculoskeletal adverse events.
Authors
- Jeyanthi Ramanarayanan
- Shifa Taj (ORCID: https://orcid.org/0000-0002-4251-7644)
- Mohammed Zuber (ORCID: https://orcid.org/0000-0002-4842-7551)
- Francisco J. Hernandez‐Ilizaliturri (ORCID: https://orcid.org/0000-0001-8054-3539)
- Lorenzo Villa Zapata (ORCID: https://orcid.org/0000-0002-3821-4595)
- Muhammed Rashid (ORCID: https://orcid.org/0000-0002-6390-7764)
- Krishna Undela (ORCID: https://orcid.org/0000-0002-7480-8761)
- Christy Thomas (ORCID: https://orcid.org/0000-0002-7559-0303)
Institutions
- Wayne Memorial Hospital (US)
- National Institute of Pharmaceutical Education and Research (IN)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1080/14740338.2025.2521358
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63